The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression

Not Applicable

Not yet recruiting

• Conditions: Depressed; Bariatric Surgery
• Interventions: Drug: Dexmedetomidine; Drug: Esketamine

• Registration Number: NCT07179913
• Lead Sponsor: The First Hospital of Jilin University

Brief Summary

The aim of this study is to observe the antidepressant effect of low-dose esketamine in obese patients with preoperative depression and seeking bariatric surgery. We speculate that intraoperative infusion and the addition of a small dose of esketamine to the postoperative analgesic pump can help reduce the proportion of patients with depression after surgery, and may further improve postoperative recovery, reduce the use of postoperative opioids, shorten postoperative hospital stay, and improve postoperative quality of life of patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-09
• Study First Submitted: 2025-09-03
• Study Start: 2025-09-10
• Study First Submitted QC: 2025-09-11
• Last Update Submitted: 2025-09-11
• Study First Posted: 2025-09-18
• Last Update Posted: 2025-09-18
• Primary Completion: 2026-09-10
• Study Completion: 2026-09-10

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Age ≥18 years old and <65 years old
• Patients with a BMI greater than 35 kg/m^2
• Hamilton Depression score ≥7 points
• Planned to undergo elective laparoscopic sleeve gastrectomy

Exclusion Criteria

• ASA ≥ grade IV
• Those who have had or are currently suffering from mental disorders other than anxiety and depression, such as schizophrenia, bipolar disorder, organic mental disorders, etc.
• Those who are unable to cooperate in completing the scale assessment
• Have received ketamine/esketamine treatment, or are allergic to ketamine/esketamine
• Clarify ischemic cardiomyopathy or severe liver and kidney dysfunction (Child pugh grade C, CKD stage G5)
• People with opioid dependence and those who have been taking various types of painkillers for a long time (more than 3 months)
• Participate in other research

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
dexmedetomidine	Dexmedetomidine	-
esketamine	Esketamine	-

Primary Outcome Measures

Name	Time	Method
Hamilton Depression Scale ≥7	Seven days after the operation	The proportion of patients with depression (Hamilton Depression score ≥7)

Secondary Outcome Measures

Name	Time	Method
the proportion of patients with depression	30 days, 3 months, 6 month and 1 year after the operation	The proportion of patients with depression